February 28, 2025

New Member: Welcome in our cluster to CAVIGEN UG

New Member: Welcome in our cluster to CAVIGEN UG
Go back

CAVIGEN develops thermoformed microstructures for cell culture, including microcavities, porous microcavities, sensor-integrated microcavities (sensor arrays), and microchannels. Its patented technology enables precise oxygen measurement in 3D cell cultures, enhancing the physiological relevance of in vitro models, improving drug development processes, and reducing the need for animal testing.

CAVIGEN’s business model follows a razor-and-blade approach, offering a measurement device alongside disposable sensor arrays for organoid generation and analysis. In addition, the company provides custom development services to integrate its microstructures into existing systems.

Target customers include pharmaceutical companies, CROs, biotech firms, and organ-on-chip manufacturers developing advanced in vitro models. Currently preparing for market entry, CAVIGEN is testing its first prototypes with academic research groups and industry partners while actively seeking strategic partners and investors to accelerate adoption within the pharmaceutical sector.

If you would like to learn more, please visit their Website.
Looking forward to your active participation!

Our latest News

discover more
Providing a cellular ‘all-clear’ signal to resume protein synthesis

Providing a cellular ‘all-clear’ signal to resume protein synthesis

Researchers’ newest technologies allow them to discover tiny protein that plays a big role in awakening dormant cells when it’s safe to resume normal operations Summary It’s a tough world for microbes. When resources grow limited and environments worsen, microbes have figured out ways to hunker down and go dormant until conditions improve. However, scientists […]

read more
Scientists uncover thousands of new proteins in ‘dark proteome’

Scientists uncover thousands of new proteins in ‘dark proteome’

An international consortium has found over 1,700 new proteins from noncoding DNA, many of which show potential as targets for cancer immunotherapy In a collaborative effort, scientists in the TransCODE consortium reveal more than 1,700 new proteins that could have implications for human diseases, including cancer. These tiny proteins were found in what’s called the […]

read more
The Plasticity of Malignant Brain Tumors as a Potential Therapeutic Approach: Sibylle Assmus Prize for Neuro-Oncology Awarded to Moritz Mall

The Plasticity of Malignant Brain Tumors as a Potential Therapeutic Approach: Sibylle Assmus Prize for Neuro-Oncology Awarded to Moritz Mall

The ability of cancer cells to change their identity makes tumors such as glioblastoma particularly aggressive and resistant to treatment. Moritz Mall, of the German Cancer Research Center (DKFZ) and the Hector Institute for Translational Brain Research (HITBR), is investigating how this plasticity can be specifically restricted. His approach focuses on genetic “guardians” that suppress […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp